Adcal D3 Caplets 112 750mg/200iu.As an adjunct to specific therapy for osteoporosis and in situations requiring therapeutic supplementation of malnutrition e.g. in pregnancy and established vitamin D dependent osteomalacia.
The prevention and treatment of calcium deficiency/vitamin D deficiency especially in the housebound and institutionalised elderly subjects. Deficiency of the active moieties is indicated by raised levels of PTH, lowered 25-hydroxy vitamin D and raised alkaline phosphatase levels which are associated with increased bone loss.
Adults and Elderly and children above 12 years of age:
Two tablets to be taken twice a day, preferably two tablets each morning and two tablets each evening.
Not recommended for children under 12 years.
Patients with mild to moderate renal failure or mild hypercalciuria should be supervised carefully including periodic checks of plasma calcium levels and urinary calcium excretion.
In patients with a history of renal stones, urinary calcium excretion should be measured to exclude hypercalciuria.
With long-term treatment it is advisable to monitor serum and urinary calcium levels and kidney function, and reduce or stop treatment temporarily if urinary calcium exceeds 7.5 mmol/24 hours (300 mg/24 hours).
Caution is required in patients receiving treatment for cardiovascular disease (see Section 4.5 â€“ thiazide diuretics and cardiac glycosides including digitalis).
Adcal-D3 Caplets should also be used with caution in other patients with increased risk of hypercalcaemia e.g. patients with sarcoidosis or those suffering from malignancies.
This product contains small quantities of sucrose.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose ma
Calcium carbonate: 750 mg equivalent to 300 mg of elemental calcium.
Colecalciferol: 200 I.U. equivalent to 5 Î¼g vitamin D3.
This product also contains sucrose (part of the vitamin D3 concentrate: approximately 0.4 milligrams per tablet).
For full list of excipientsTablet Core:
Colloidal silicon dioxide
Modified food starch
Sodium ascorbate cryst.
Medium chain triglycerides
Iron oxide yellow
Iron oxide red
The use of calcium supplements has, rarely, given rise to mild gastro-intestinal disturbances, such as constipation, flatulence, nausea, gastric pain or diarrhoea. Following administration of vitamin D supplements occasional skin rash has been reported. Hypercalciuria, and in rare cases hypercalcaemia, have been seen with long term treatment at high dosages.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme.